title: [Current status of clinical development of novel anti-diabetic drugs].
abstract: Clinical development of novel antidiabetic drugs, such as GK activator, GPR40 agonist, GPR119 agonist, 11β-HSD1 inhibitor and trelagliptin, has been progressing over the world. Especially, GK activator, GPR40 agonist, GPR119 agonist and 112-HSD1 inhibitor have unique action mechanism compared to existing drugs. GK activator potentiates glucose-stimulated insulin secretion from β cells and stimulates glucose uptake into the liver. GPR40 agonists and GPR119 agonist stimulate glucose-dependent insulin secretion from β cells. 11β-HSD1 inhibitor reduces the conversion of cortisone to cortisol. Trelagliptin is a long acting dipeptidyl peptidase-4(DPP-4) inhibitor and a once-weekly treatment by trelagliptin would improve the drug adherence of patients. This article focuses on these new and emerging diabetes agents.
authors: Hiroshi
authors: H
authors: Kamiyama
authors: Yasuo
authors: Y
authors: Terauchi
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors; D000818:Animals; D044482:Benzeneacetamides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D051379:Mice; D043562:Receptors, G-Protein-Coupled / Q000819:agonists
chemical_list: D044482:Benzeneacetamides; D054873:Dipeptidyl-Peptidase IV Inhibitors; C473034:FFAR1 protein, human; C519854:GPR119 protein, human; D007004:Hypoglycemic Agents; D043562:Receptors, G-Protein-Coupled; C553963:piragliatin; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1